Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.59 |
| ▸ | CASP2 | P42575 | 1/20 | 0.58 |
| ▸ | OTC | P00480 | 1/20 | 0.54 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.51 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.49 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.49 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.49 |
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | RRM1 | P23921 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13311701 | 1.00 | NOD1 (0.59) | NOD1CASP2OTCDPP7DDAH1 | |
| SCHEMBL1422751 | 1.00 | NOD1 (0.59) | NOD1CASP2OTCDPP7DDAH1 | |
| SCHEMBL16860748 | 0.95 | NOD1 (0.60) | NOD1CASP2OTCDPP7DDAH1 | |
| SCHEMBL16860728 | 0.95 | NOD1 (0.60) | NOD1CASP2OTCDPP7DDAH1 | |
| SCHEMBL27455405 | 0.92 | NOD1 (0.65) | NOD1CASP2OTCDPP7DDAH1 | |
| SCHEMBL20162087 | 0.90 | NOD1 (0.71) | NOD1CASP2OTCDPP7GNAI3 | |
| SCHEMBL17393486 | 0.90 | NOD1 (0.71) | NOD1CASP2OTCDPP7GNAI3 | |
| SCHEMBL358468 | 0.89 | NOD1 (0.74) | NOD1CASP2DPP7GNAI3GNAO1 | |
| SCHEMBL2386271 | 0.89 | NOD1 (0.74) | NOD1CASP2DPP7GNAI3GNAO1 | |
| SCHEMBL308741 | 0.89 | NOD1 (0.74) | NOD1CASP2DPP7GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036912-A | Cytokine conjugates for the treatment of proliferative and infectious diseases | 辛索克斯公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4684030-A2 | METHOD OF DEPROTECTING AT LEAST ONE D-AMINO ACID AND/OR D-AMINO ACID DERIVATIVE PROTECTED FUNCTIONAL GROUP | Martin-Luther-Universität Halle-Wittenberg (DE) | 2026-01-28 | — | — | EP | disclosed |
| US-12521437-B2 | IL-2 conjugates and methods of use thereof | Synthorx, Inc. (US) | 2026-01-13 | — | — | US | disclosed |
| US-12491254-B2 | Interleukin 10 conjugates and uses thereof | Synthorx, Inc. (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250325632-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | Synthorx, Inc. (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250325633-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Synthorx, Inc. (US) | 2025-10-23 | — | — | US | disclosed |
| EP-3876973-B1 | INTERLEUKIN 10 CONJUGATES AND USES THEREOF | SYNTHORX INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12377131-B2 | Cytokine conjugates for the treatment of autoimmune diseases | Synthorx, Inc. (US) | 2025-08-05 | — | — | US | disclosed |
| US-12344648-B2 | IL-15 conjugates and uses thereof | Synthrox, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-12318431-B2 | Cytokine conjugates for the treatment of proliferative and infectious diseases | Synthorx, Inc. (US) | 2025-06-03 | — | — | US | disclosed |
| US-20200181220-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | SYNTHORX INC (US) | 2020-06-11 | — | — | US | disclosed |
| EP-3661955-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Synthorx, Inc. (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-3661956-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | Synthorx, Inc. (US) | 2020-06-10 | — | — | EP | disclosed |
| CN-111194322-A | Cytokine conjugates for the treatment of proliferative and infectious diseases | 辛索克斯公司 | 2020-05-22 | — | — | CN | disclosed |
| CN-111183149-A | Cytokine conjugates for the treatment of autoimmune diseases | 辛索克斯公司 | 2020-05-19 | — | — | CN | disclosed |
| US-10610571-B2 | Cytokine conjugates for the treatment of proliferative and infectious diseases | Synthorx, Inc. (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190314455-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | SANOFI (FR) | 2019-10-17 | — | — | US | disclosed |
| WO-2019165453-A1 | IL-15 CONJUGATES AND USES THEREOF | Synthorx, Inc. (US) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019028419-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | Synthorx, Inc. (US) | 2019-02-07 | — | — | WO | disclosed |
| WO-2019028425-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Synthorx, Inc. (US) | 2019-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12491254-B2 | Interleukin 10 conjugates and uses thereof | IL2, CCR10, IL2RA | NOD1 761/4885CASP2 607/4885OTC 1143/4885 |
| US-20250325633-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | IL2, IL2RA, IL15 | NOD1 584/4885CASP2 201/4885OTC 1738/4885 |
| US-12318431-B2 | Cytokine conjugates for the treatment of proliferative and infectious diseases | IL2, IL2RA, IL36G | NOD1 1106/4885CASP2 153/4885OTC 2155/4885 |
| US-20200181220-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | IL2, IL2RA, IL36G | NOD1 1106/4885CASP2 153/4885OTC 2155/4885 |
| US-20190314455-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | IL2, IL2RA, IL36G | NOD1 1106/4885CASP2 153/4885OTC 2155/4885 |
| US-10610571-B2 | Cytokine conjugates for the treatment of proliferative and infectious diseases | IL2, IL2RA, IL36G | NOD1 1106/4885CASP2 153/4885OTC 2155/4885 |
| US-20250325632-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | IL2, IL2RA, IL36G | NOD1 1106/4885CASP2 153/4885OTC 2155/4885 |
| US-12377131-B2 | Cytokine conjugates for the treatment of autoimmune diseases | IL2, IL2RA, IL15 | NOD1 584/4885CASP2 201/4885OTC 1738/4885 |
| US-12344648-B2 | IL-15 conjugates and uses thereof | IL15, IL15RA, IL5 | NOD1 772/4885CASP2 1318/4885OTC 2039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.